NYSE - Delayed Quote ? USD Charles River Laboratories International, Inc. (CRL) Follow Compare 187.74 -9.16 (-4.65%) At close: November 15 at 4:00 PM EST 187.74 0.00 (0.00%) After hours: November 15 at 6:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Charles River (CRL) International Revenue in Focus: Trends and Expectations Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects. Zacks ? 6 days ago CRL -4.65% ^GSPC Charles River Laboratories to Present at UBS and Jefferies Conferences WILMINGTON, Mass., November 11, 2024--Charles River Laboratories to Present at UBS and Jefferies Conferences Business Wire ? 6 days ago CRL -4.65% Charles River Laboratories International Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags Charles River Laboratories International ( NYSE:CRL ) Third Quarter 2024 Results Key Financial Results Revenue... Simply Wall St. ? 9 days ago CRL -4.65% Q3 2024 Charles River Laboratories International Inc Earnings Call Q3 2024 Charles River Laboratories International Inc Earnings Call Thomson Reuters StreetEvents ? 10 days ago CRL -4.65% Charles River Laboratories International Inc (CRL) Q3 2024 Earnings Call Highlights: Navigating ... Despite a slight revenue decline, Charles River Laboratories International Inc (CRL) showcases robust cash flow and strategic initiatives to drive future growth. GuruFocus.com ? 11 days ago CRL -4.65% Decoding Charles River Laboratories International Inc (CRL): A Strategic SWOT Insight Insightful Analysis of CRL's Financial Health and Strategic Positioning GuruFocus.com ? 11 days ago CRL -4.65% Charles River's Q3 Earnings, Revenues Beat Estimates, Margins Fall CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is more than offset by lower revenues in the DSA segment. Zacks ? 11 days ago CRL -4.65% RMD +1.43% BSX Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. Zacks ? 11 days ago CRL -4.65% Charles River Laboratories (CRL) Q3 Earnings and Revenues Beat Estimates Charles River (CRL) delivered earnings and revenue surprises of 6.58% and 3.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 11 days ago CRL -4.65% Charles River: Q3 Earnings Snapshot On a per-share basis, the Wilmington, Massachusetts-based company said it had profit of $1.33. Earnings, adjusted for non-recurring costs, were $2.59 per share. The results exceeded Wall Street expectations. Associated Press Finance ? 11 days ago CRL -4.65% Charles River Laboratories Announces Third-Quarter 2024 Results WILMINGTON, Mass., November 06, 2024--Charles River Laboratories issues its third-quarter 2024 financial results Business Wire ? 11 days ago CRL -4.65% Gear Up for Charles River (CRL) Q3 Earnings: Wall Street Estimates for Key Metrics Evaluate the expected performance of Charles River (CRL) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. Zacks ? 13 days ago CRL -4.65% Pediatrix Medical Group (MD) Surpasses Q3 Earnings and Revenue Estimates Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 18.92% and 2.21%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 16 days ago CRL -4.65% Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy? Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Zacks ? 18 days ago CRL -4.65% SHC Why Charles River (CRL) is Poised to Beat Earnings Estimates Again Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. Zacks ? 19 days ago CRL -4.65% CRL Gears Up for Q3 Earnings: Here's What You Need to Know Growth across all businesses within the Manufacturing segment is likely to have contributed to Charles River's Q3 revenues, offset by lower biopharmaceutical demand. Zacks ? 26 days ago CRL -4.65% FibroBiologics and Charles River link for chronic disease therapies manufacture Charles River will act as the contract development and manufacturing organisation for FibroBiologics. Pharmaceutical Technology ? 27 days ago FBLG CRL -4.65% CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch Charles River launches Retrogenix Non-Human Protein Library to provide early insights into how therapeutics interact with non-human protein targets in vitro. Zacks ? 30 days ago CRL -4.65% Charles River Launches New Retrogenix? Non-Human Protein Library WILMINGTON, Mass., October 17, 2024--Charles River launches the Retrogenix? Non-Human Protein Library to support assessment of off-target binding, de-risk studies & aid model selection. Business Wire ? last month CRL -4.65% Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call WILMINGTON, Mass., October 16, 2024--Charles River Laboratories schedules third-quarter 2024 earnings release and conference call. Business Wire ? last month CRL -4.65% Performance Overview Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return CRL S&P 500 YTD -20.58% +23.08% 1-Year +5.25% +30.58% 3-Year -51.35% +25.36%
